OpenAI Unveils GPT-Rosalind: A Specialized AI Model for Drug Discovery and Life Sciences Research

Named after the crystallographer who helped reveal the structure of DNA, GPT-Rosalind is OpenAI’s first domain-specific model series, fine-tuned for biochemistry, genomics, and protein engineering. Access is restricted to a trusted-access programme for vetted enterprise customers including Amgen, Moderna, and Thermo Fisher Scientific. OpenAI has launched GPT-Rosalind, a frontier reasoning model built specifically for life […]

This story continues at The Next Web

Stockholm’s BioLamina secures €20M EIB loan to scale protein matrices essential for cell therapies

The European Investment Bank is lending €20 million to BioLamina, the Swedish biotech that supplies the laminin-based cell culture matrices used by stem cell therapy developers worldwide. The funding will support expanded production of laminin technologies and animal-free drug safety testing methods. BioLamina, the Stockholm-based biotechnology company that produces the protein scaffolding used to grow […]

This story continues at The Next Web

Envision AESC, backed by GIC, considers a $2 billion Hong Kong IPO

The Japan-headquartered EV battery manufacturer, controlled by China’s Envision Group and backed by Singapore’s sovereign wealth fund GIC, is mulling an IPO in Hong Kong that could raise up to $2 billion, Bloomberg reported on Thursday. The move marks a significant change from earlier plans to list in the US. Envision AESC, the electric vehicle […]

This story continues at The Next Web

Sequoia Secures $7 Billion for Largest Late-Stage Fund Yet

The Silicon Valley institution has closed roughly $7 billion for its expansion strategy fund, nearly doubling its comparable 2022 vehicle. Alfred Lin and Pat Grady, who took over as co-stewards in November 2025, are making the raise their opening statement on the AI era. Sequoia Capital has raised approximately $7 billion for a new fund, […]

This story continues at The Next Web

reBot Arm B601-DM: Open-Source 6+1 DoF Robotic Arm for Embodied AI and Teleoperation

reBot Arm B601 DM Bundle

Seeed Studio reBot Arm B601-DM is a fully open-source 6-axis robotic arm (plus a parallel gripper) designed to lower the barrier to entry for embodied AI learning and teleoperation. Built around high-performance Damiao actuators, the arm offers up to 767mm of reach, a 1.5kg payload capacity, and high-precision 0.2mm repeatability. Designed for researchers and robotics developers, the B601-DM is compatible out of the box with major AI and robotics frameworks, including ROS 1/2, Hugging Face’s LeRobot, NVIDIA Isaac Sim, and Pinocchio. Seeed Studio reBot Arm B601-DM specifications: Communication – CAN bus @ 1Mbps) and UART @ 921600bps Degrees of Freedom (DOF) – 6-axis arm + 1 parallel gripper Motors / Actuators – 7x Damiao motors 4x DAMIAO 4310 (DM-J4310-2EC) 3x DAMIAO 4340P (DM-J4340P-2EC) high-torque motors Payload – 1.5kg (without gripper, at recommended 70% reach) Reach – 767mm (with gripper), 607mm (without gripper) Repeatability – < 0.2 mm Joint torque and […]

The post reBot Arm B601-DM – An open-source 6+1 DoF robotic arm for embodied AI and teleoperation applications appeared first on CNX Software – Embedded Systems News.